Inactivation of 12 viruses by heating steps applied during manufacture of a hepatitis B vaccine
Identifieur interne : 001D34 ( Main/Exploration ); précédent : 001D33; suivant : 001D35Inactivation of 12 viruses by heating steps applied during manufacture of a hepatitis B vaccine
Auteurs : P. N. Lelie [Pays-Bas] ; H. W. Reesink [Pays-Bas] ; C. J. Lucas [Pays-Bas]Source :
- Journal of Medical Virology [ 0146-6615 ] ; 1987-11.
Abstract
The efficacy of two heating cycles (90 sec at 103°C and 10 hr at 65°C) used during manufacture of a plasma‐derived hepatitis‐B vaccine was validated for the inactivation of 12 virus families. A period of 15 min warming up to 65°C had already completely inactivated representatives of nine virus families, ie, poxvirus (vaccinia), picornavirus (encephalomyocarditis virus), togavirus (sind bis virus), coronavirus (mouse hepatitis virus), orthomyxovirus (influenza virus), rhabdovirus (vesicular stomatitis virus), herpes virus (cytomegalovirus), lentivirus (human immunodeficiency virus), and retrovirus (murine leukemia virus). After prolonged heating at 65°C or heating for 90 sec at 103°C, parvovirus (canine parvovirus) and the phage phiX174 were also completely inactivated. Papovavirus represented by simian virus 40 (SV‐40) was the most heat‐resistant virus evaluated. The infectivity of SV‐40 was reduced by 104 Tissue Culture Infectious Doses (TCID50) per ml after 90 sec at 103°C, but a marginal residual activity (<5 TCID50 per ml) was observed. Subsequent pasteurization for 10 h at 65°C did not further reduce the infectivity of SV‐40. This study shows that the two heat‐inactivation steps used during the production of this vaccine kill a wide variety of viruses that might be present in human blood.
Url:
DOI: 10.1002/jmv.1890230313
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000411
- to stream Istex, to step Curation: 000378
- to stream Istex, to step Checkpoint: 000705
- to stream Main, to step Merge: 001D56
- to stream Main, to step Curation: 001D34
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Inactivation of 12 viruses by heating steps applied during manufacture of a hepatitis B vaccine</title><author><name sortKey="Lelie, P N" sort="Lelie, P N" uniqKey="Lelie P" first="P. N." last="Lelie">P. N. Lelie</name></author><author><name sortKey="Reesink, H W" sort="Reesink, H W" uniqKey="Reesink H" first="H. W." last="Reesink">H. W. Reesink</name></author><author><name sortKey="Lucas, C J" sort="Lucas, C J" uniqKey="Lucas C" first="C. J." last="Lucas">C. J. Lucas</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:50F3F998B53D3E728D8A8ED94FCD5E8A69DA41E3</idno><date when="1987" year="1987">1987</date><idno type="doi">10.1002/jmv.1890230313</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-09VZ1HRS-D/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000411</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000411</idno><idno type="wicri:Area/Istex/Curation">000378</idno><idno type="wicri:Area/Istex/Checkpoint">000705</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000705</idno><idno type="wicri:doubleKey">0146-6615:1987:Lelie P:inactivation:of:viruses</idno><idno type="wicri:Area/Main/Merge">001D56</idno><idno type="wicri:Area/Main/Curation">001D34</idno><idno type="wicri:Area/Main/Exploration">001D34</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Inactivation of 12 viruses by heating steps applied during manufacture of a hepatitis B vaccine</title><author><name sortKey="Lelie, P N" sort="Lelie, P N" uniqKey="Lelie P" first="P. N." last="Lelie">P. N. Lelie</name><affiliation wicri:level="4"><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Central Laboratory of the Netherlands Red Cross Blood Transfusion Service and Laboratory for Experimental and Clinical Immunology, University of Amsterdam, Amsterdam</wicri:regionArea><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName><orgName type="university">Université d'Amsterdam</orgName></affiliation><affiliation wicri:level="1"><country xml:lang="fr" wicri:curation="lc">Pays-Bas</country><wicri:regionArea>Correspondence address: Publication Secretariat, Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, P.O. Box 9406, 1006 AK Amsterdam</wicri:regionArea><wicri:noRegion>1006 AK Amsterdam</wicri:noRegion></affiliation></author><author><name sortKey="Reesink, H W" sort="Reesink, H W" uniqKey="Reesink H" first="H. W." last="Reesink">H. W. Reesink</name><affiliation wicri:level="4"><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Central Laboratory of the Netherlands Red Cross Blood Transfusion Service and Laboratory for Experimental and Clinical Immunology, University of Amsterdam, Amsterdam</wicri:regionArea><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName><orgName type="university">Université d'Amsterdam</orgName></affiliation></author><author><name sortKey="Lucas, C J" sort="Lucas, C J" uniqKey="Lucas C" first="C. J." last="Lucas">C. J. Lucas</name><affiliation wicri:level="4"><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Central Laboratory of the Netherlands Red Cross Blood Transfusion Service and Laboratory for Experimental and Clinical Immunology, University of Amsterdam, Amsterdam</wicri:regionArea><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName><orgName type="university">Université d'Amsterdam</orgName></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Journal of Medical Virology</title><title level="j" type="alt">JOURNAL OF MEDICAL VIROLOGY</title><idno type="ISSN">0146-6615</idno><idno type="eISSN">1096-9071</idno><imprint><biblScope unit="vol">23</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="297">297</biblScope><biblScope unit="page" to="301">301</biblScope><biblScope unit="page-count">5</biblScope><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>New York</pubPlace><date type="published" when="1987-11">1987-11</date></imprint><idno type="ISSN">0146-6615</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0146-6615</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The efficacy of two heating cycles (90 sec at 103°C and 10 hr at 65°C) used during manufacture of a plasma‐derived hepatitis‐B vaccine was validated for the inactivation of 12 virus families. A period of 15 min warming up to 65°C had already completely inactivated representatives of nine virus families, ie, poxvirus (vaccinia), picornavirus (encephalomyocarditis virus), togavirus (sind bis virus), coronavirus (mouse hepatitis virus), orthomyxovirus (influenza virus), rhabdovirus (vesicular stomatitis virus), herpes virus (cytomegalovirus), lentivirus (human immunodeficiency virus), and retrovirus (murine leukemia virus). After prolonged heating at 65°C or heating for 90 sec at 103°C, parvovirus (canine parvovirus) and the phage phiX174 were also completely inactivated. Papovavirus represented by simian virus 40 (SV‐40) was the most heat‐resistant virus evaluated. The infectivity of SV‐40 was reduced by 104 Tissue Culture Infectious Doses (TCID50) per ml after 90 sec at 103°C, but a marginal residual activity (<5 TCID50 per ml) was observed. Subsequent pasteurization for 10 h at 65°C did not further reduce the infectivity of SV‐40. This study shows that the two heat‐inactivation steps used during the production of this vaccine kill a wide variety of viruses that might be present in human blood.</div></front></TEI><affiliations><list><country><li>Pays-Bas</li></country><region><li>Hollande-Septentrionale</li></region><settlement><li>Amsterdam</li></settlement><orgName><li>Université d'Amsterdam</li></orgName></list><tree><country name="Pays-Bas"><region name="Hollande-Septentrionale"><name sortKey="Lelie, P N" sort="Lelie, P N" uniqKey="Lelie P" first="P. N." last="Lelie">P. N. Lelie</name></region><name sortKey="Lelie, P N" sort="Lelie, P N" uniqKey="Lelie P" first="P. N." last="Lelie">P. N. Lelie</name><name sortKey="Lucas, C J" sort="Lucas, C J" uniqKey="Lucas C" first="C. J." last="Lucas">C. J. Lucas</name><name sortKey="Reesink, H W" sort="Reesink, H W" uniqKey="Reesink H" first="H. W." last="Reesink">H. W. Reesink</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001D34 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001D34 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= CovidV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:50F3F998B53D3E728D8A8ED94FCD5E8A69DA41E3
|texte= Inactivation of 12 viruses by heating steps applied during manufacture of a hepatitis B vaccine
}}
| This area was generated with Dilib version V0.6.33. |  |